Cambridge-based biotech startup Tolemy Bio raised 1.4 million EUR in pre-seed funding. The round was led by Norrsken Evolve, with participation from Big Sur Ventures, JME Ventures, Masia, and a new UK-based stealth fund. The company will use the funding to expand its data generation, machine learning, and engineering capabilities, continue development of its Orbit platform, and support early customer and partner deployments. While headquartered in Cambridge, much of its operational activity will continue from Barcelona.
About Tolemy Bio
Tolemy Bio is a biotech startup developing Orbit, an AI-enabled cell biology platform designed to help biopharma teams better understand, interpret, and optimise living cells used in modern therapies and drug development. The platform connects laboratory tools and experimental data sources in a single AI-native environment and incorporates virtual cell models and AI research agents to support analysis of cellular behaviour and experimental decision-making.
Cambridge, United Kingdom
Read Company ProfileFrequently Asked Questions
What type of funding round did Tolemy Bio raise?
Tolemy Bio raised a pre-seed round.
How much did Tolemy Bio raise in its pre-seed?
Tolemy Bio raised $1,400,000 EUR in its pre-seed.
When did Tolemy Bio raise its pre-seed?
Tolemy Bio raised its pre-seed on 2026-05-12.
Who invested in Tolemy Bio's pre-seed?
The investors in Tolemy Bio's pre-seed are: Norrsken Evolve, Big Sur Ventures, JME Ventures, Masia, a new UK-based stealth fund.
What type of investment was Tolemy Bio's pre-seed?
Tolemy Bio's pre-seed was a equity investment.
How will Tolemy Bio use the funds from its pre-seed?
Tolemy Bio plans to use the funds for: expand data generation capabilities, expand machine learning capabilities, expand engineering capabilities, continue development of Orbit, support early customer and partner deployments.